US 9,808,465 B2
Emulsion formulations of aprepitant
Thomas B. Ottoboni, Belmont, CA (US); and Han Han, Mountain View, CA (US)
Assigned to Heron Therapeutics, Inc., Redwood City, CA (US)
Filed by Heron Therapeutics, Inc., Redwood City, CA (US)
Filed on Sep. 18, 2015, as Appl. No. 14/859,013.
Claims priority of provisional application 62/052,948, filed on Sep. 19, 2014.
Prior Publication US 2016/0082013 A1, Mar. 24, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/5355 (2006.01); A61K 31/5377 (2006.01); A61K 9/107 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61K 47/44 (2017.01); A61K 31/573 (2006.01); A61K 47/18 (2017.01)
CPC A61K 31/5377 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0024 (2013.01); A61K 9/107 (2013.01); A61K 31/573 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/18 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method for preventing or treating a subject at risk of or suffering from emesis, comprising administering to the subject a composition comprising an injectable physically stable emulsion wherein the emulsion comprises:
aprepitant;
11 wt/wt % to 15 wt/wt % of an emulsifier; an oil;
a co-emulsifier which is an alcohol; a tonicity modifier; a pH modifier; and water;
wherein the ratio of emulsifier:aprepitant ranges from about 18:1 to 22:1, and
wherein the pH of the emulsion ranges from about 7.5 to 9.0.